24 Jan 2023 , 12:33 PM
Dr. Reddy’s Laboratories could post healthy growth in US sales during the quarter, following continued momentum in niche products. Domestic business could post 6-7% revenue growth over the year-ago quarter, with gastro, respiratory and cardiac therapies taking the lead. Analysts at IIFL Securities expect revenue to grow 17% over the year-ago quarter and decline 2% sequentially. Exluding Revlimid, growth could be subdued.
Key margin pressures include price pressures in US, high input cost inflation and integration of low-margin Cidmus brand in India.
The company is likely to post 39% in Profit After Tax (PAT) over the year-ago quarter.
Important management insights to watch out for:
December 2022 estimates |
YoY change |
QoQ change |
|
Revenue (Rs mn) |
62,016 |
17% |
(2)% |
EBITDA (Rs mn) |
15,339 |
28% |
(15)% |
EBITDA margin |
24.7% |
214 bps |
(383) bps |
Profit After Tax (Rs mn) |
9,919 |
39% |
(3)% |
Source: IIFL Research
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.